medwireNews : The FDA has approved extending use of dulaglutide to children and adolescents aged 10 years or older who have type 2 diabetes.

Dulaglutide delivers significant reductions in glucose levels for youths with type 2 diabetes, report the AWARD-PEDS investigators.

Long-term dulaglutide use may reduce the incidence of moderate or severe erectile dysfunction in men with type 2 diabetes, particularly those with underlying cardiovascular disease, shows an exploratory analysis of REWIND data.

Dulaglutide doses of 3.0 and 4.5 mg are significantly more efficacious than the standard doses, with similar safety profiles, report the AWARD 11 investigators.

Participants in the REWIND trial achieved a significant reduction in total cardiovascular disease burden with dulaglutide versus placebo, report the investigators.

Dulaglutide is associated with better treatment persistence and lower rates of treatment modification versus other glucagon-like peptide‑1 receptor agonists in people with type 2 diabetes, suggests a study of Swedish health registries.

Results from the D-LIFT trial suggest a reduction in liver fat content when dulaglutide, a glucagon-like peptide-1 receptor agonist, is added to standard care treatment in people with concurrent type 2 diabetes and non-alcoholic fatty liver disease.

The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.

Semaglutide has delivered better glycemic control and weight reduction than dulaglutide for patients with type 2 diabetes in the SUSTAIN 7 trial.

Once-weekly dulaglutide lowers glycated hemoglobin levels to a similar degree to titrated daily insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease, study findings indicate.

Tuttle KR et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30104-9

Wang W et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13506

And a significant difference versus dulaglutide (60%) was seen with the 8.0 mg slow escalation and 12.0 mg doses.

Read our quick round-up of the AWARD trials of the GLP-1 receptor agonist dulaglutide in people with type 2 diabetes.

SURPASS-SWITCH: Recruiting Trial population: People taking dulaglutide, with or without other antihyperglycemic medications Comparator treatment: Dulaglutide NCT05564039 ; estimated primary study completion in June 2024 For this trial, people already taking dulaglutide will either continue on the medication or switch to tirzepatide.

They also observed dose-dependent reductions in bodyweight with tirzepatide compared with dulaglutide.

In this trial, LY3437943 was tested in 72 people with type 2 diabetes, given as subcutaneous injections at doses ranging from 0.5 to 12 mg/week, and compared with dulaglutide 1.5 mg (not titrated up from 0.75 mg) and placebo.

The primary endpoint was adverse events up to approximately week 57, reported in up to 85% of participants taking semaglutide and 82% of those taking dulaglutide.